source
- BridgeBio eyes first FDA approval for limb-girdle muscular dystrophy therapyBridgeBio Pharma is preparing for a potential launch of its experimental drug BBP-418 aimed at treating limb-girdle muscular dystrophy type 2I/R9, pending FDA decision. The agency has set a review…
- Teva halts phase 2 trial of emrusolmin for multiple system atrophy after futility analysisTeva Pharmaceuticals announced it is stopping a phase 2 study of its experimental small‑molecule drug emrusolmin, which was being tested in patients with the rare neurodegenerative condition multip…